Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye tests could spot silent vision damage in lupus patients

NCT ID NCT07679776

Knowledge-focused Sponsor: The First Affiliated Hospital of Anhui Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates whether people with systemic lupus erythematosus (SLE) show early signs of retinal damage before they notice any vision problems. Researchers will use advanced eye imaging and vision tests to compare lupus patients with healthy volunteers. The goal is to find markers that could help doctors detect and treat eye involvement earlier, potentially preserving vision and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify early warning signs of eye damage in lupus patients, allowing doctors to intervene sooner and potentially prevent vision loss.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to direct improvements in care, and the findings might not apply to all lupus patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 50 patients ( 100 eyes ) who met the inclusion criteria were collected from the patients diagnosed with SLE in the Department of Rheumatology and Immunology of the First Affiliated Hospital of Anhui Medical University. Among them, the diagnosis of SLE is based on the 2019 European Rheumatism Association ( EULAR ) / American Rheumatism Association ( ACR ) SLE diagnostic criteria. At the same time, 50 age-matched healthy adults ( 100 eyes ) were recruited as the normal control group.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * the best corrected visual acuity ( BCVA ) of all cases must be ≥ 1.0 according to the international standard visual acuity char; * intraocular pressure ( IOP ) in the normal range, namely 10 mmHg ≤ IOP ≤ 21 mmHg ; * visual field meter examination center and peripheral visual field without defect ; * no degeneration of fundus retina ; Exclusion Criteria: * obvious abnormality in cranial MRI ; * history of glaucoma, cataract, retinal vascular disease, retinitis pigmentosa and other eye diseases ; * history of refractive surgery such as corneal refractive surgery and cataract surgery ; * other major disease history or systemic lesions affecting the eye ; * history of disease affecting cognitive function, can understand and cooperate with the examination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic lupus erythematosus (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic lupus erythematosus (SLE) Visual function

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.